An attempt at applying epiadriamycin to the patients for whom doxorubicin is cardiologically contraindicated.
Administrating Epi-ADR (Epiadriamycin) to the patients for whom ADR was cardiologically contraindicated did not cause significant complications. No complications occurred in the patients treated with Epiadriamycin, after they had completed a full course of maximal dose of ADR. The trial was conducted in close cooperation with a cardiological intensive care unit which is an essential arrangement in such clinical situation, until the optimal therapeutical method of administrating Epi-ADR is defined with special attention devoted to its critical dose.
Pawlicki
M
M
Zuchowska-Vogelgesang
B
B
Maciejewicz
J
J
Kojder
R
R
D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use*; D015251:Epirubicin; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013237:Stereoisomerism
D015251:Epirubicin; D004317:Doxorubicin